Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adagene
Biotech
Third Arc Bio teams up with Adagene to create T-cell engagers
Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers.
Gabrielle Masson
Nov 13, 2025 10:45am
Merck KGaA lands new R&D chief—Chutes & Ladders
Sep 5, 2025 8:30am
Sanofi takes up option on Adagene bispecific, invests $25M
Jul 1, 2025 8:10am
ADC Therapeutics calls it quits on Adagene solid tumor collab
Aug 31, 2023 10:24am
Sanofi looks for a 'safe' bet in $2.5B tie up for Adagene tech
Mar 2, 2022 6:00am
Adagene plans $125M IPO to challenge BMS and Pfizer
Jan 20, 2021 9:00am
